
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7067821/publications.pdf Version: 2024-02-01



Μίναν Κ Ράτμι

#	Article	IF	CITATIONS
1	Sharing of clinical trial data among trialists: a cross sectional survey. BMJ, The, 2012, 345, e7570-e7570.	6.0	112
2	Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. JAMA - Journal of the American Medical Association, 2015, 314, 604.	7.4	87
3	Industry Ties in Otolaryngology. Otolaryngology - Head and Neck Surgery, 2015, 152, 993-999.	1.9	70
4	First-Year Report Cards From the Merit-Based Incentive Payment System (MIPS). JAMA - Journal of the American Medical Association, 2019, 321, 1157.	7.4	36
5	Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021. JAMA - Journal of the American Medical Association, 2021, 326, 184.	7.4	32
6	How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?. Clinical Orthopaedics and Related Research, 2016, 474, 1053-1068.	1.5	26
7	Risk factors for thirtyâ€day readmission following flap reconstruction of oncologic defects of the head and neck. Laryngoscope, 2018, 128, 343-349.	2.0	23
8	Modernizing the FDA's 510(k) Pathway. New England Journal of Medicine, 2019, 381, 1891-1893.	27.0	23
9	Assessment of Gender Differences in Clinical Productivity and Medicare Payments Among Otolaryngologists in 2017. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 822.	2.2	21
10	Early experience with the FDA's Breakthrough Devices program. Nature Biotechnology, 2020, 38, 933-938.	17.5	20
11	Patient Preferences in Subglottic Stenosis Treatment: A Discrete Choice Experiment. Otolaryngology - Head and Neck Surgery, 2018, 158, 520-526.	1.9	17
12	Analysis of Price Transparency for Oncologic Surgery Among National Cancer Institute–Designated Cancer Centers in 2020. JAMA Surgery, 2021, 156, 582.	4.3	16
13	Telemedicine Services Provided to Medicare Beneficiaries by Otolaryngologists Between 2010 and 2018. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 816.	2.2	15
14	Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019. JAMA Internal Medicine, 2020, 180, 1701.	5.1	15
15	Trends in Ambulatory Surgery Center Utilization for Otolaryngologic Procedures among Medicare Beneficiaries, 2010â€2017. Otolaryngology - Head and Neck Surgery, 2020, 162, 873-880.	1.9	15
16	Payer-Negotiated Prices for Telemedicine Services. Journal of General Internal Medicine, 2022, 37, 3495-3497.	2.6	14
17	The role of industry influence in sinus balloon dilation: Trends over time. Laryngoscope, 2018, 128, 1540-1545.	2.0	13
18	The Meritâ€based Incentive Payment System (MIPS): A Primer for Otolaryngologists. Otolaryngology - Head and Neck Surgery, 2018, 159, 410-413.	1.9	13

#	Article	IF	CITATIONS
19	Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance. JAMA Internal Medicine, 2022, 182, 603.	5.1	13
20	What Do Patients Want from Otolaryngologists? A Discrete Choice Experiment. Otolaryngology - Head and Neck Surgery, 2017, 157, 618-624.	1.9	12
21	Getting More Savings from ACOs — Can the Pace Be Pushed?. New England Journal of Medicine, 2019, 380, 2190-2192.	27.0	12
22	Otolaryngologist Performance in the Merit-Based Incentive Payment System in 2017. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 639.	2.2	11
23	Using Machine Learning to Predict Operating Room Case Duration: A Case Study in Otolaryngology. Otolaryngology - Head and Neck Surgery, 2023, 168, 241-247.	1.9	11
24	Postmarket Modifications of High-Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration. Otolaryngology - Head and Neck Surgery, 2015, 153, 400-408.	1.9	10
25	Bundled Payments in Otolaryngology: Early Lessons from Arkansas. Otolaryngology - Head and Neck Surgery, 2018, 159, 945-947.	1.9	10
26	Private Payer–Negotiated Prices for Outpatient Otolaryngologic Surgery. Otolaryngology - Head and Neck Surgery, 2022, 167, 262-265.	1.9	10
27	The US Food and Drug Administration 515 Program Initiative. JAMA Cardiology, 2016, 1, 117.	6.1	9
28	Medicare's New Device-Coverage Pathway — Breakthrough or Breakdown?. New England Journal of Medicine, 2021, 384, e43.	27.0	9
29	Industry Sponsorship of Research in Otolaryngology. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 842.	2.2	8
30	Regulation of Over-the-Counter Hearing Aids — Deafening Silence from the FDA. New England Journal of Medicine, 2020, 383, 1997-2000.	27.0	8
31	US Food and Drug Administration Clearance of Moderate-Risk Otolaryngologic Devices via the 510(k) Process, 1997-2016. Otolaryngology - Head and Neck Surgery, 2017, 157, 608-617.	1.9	7
32	Use of Corticosteroid-Eluting Sinus Stents Between 2012 and 2017. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 90.	2.2	7
33	Female Authorship of Opinion Pieces in Leading Otolaryngology Journals between 2013 and 2018. Otolaryngology - Head and Neck Surgery, 2020, 162, 35-37.	1.9	7
34	Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011. JAMA Network Open, 2020, 3, e2014496.	5.9	7
35	Pneumonia, urinary tract infection, bacteremia, and Clostridioides difficile infection following major head and neck free and pedicled flap surgeries. Oral Oncology, 2021, 122, 105541.	1.5	7
36	Implications of Private Equity Acquisition of Otolaryngology Physician Practices. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 97.	2.2	6

#	Article	IF	CITATIONS
37	Private payerâ€negotiated prices for FDAâ€approved biologic treatments for allergic diseases. International Forum of Allergy and Rhinology, 2022, 12, 798-801.	2.8	6
38	Outâ€ofâ€pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. International Forum of Allergy and Rhinology, 2022, 12, 1295-1298.	2.8	6
39	Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013. JAMA Internal Medicine, 2016, 176, 551.	5.1	5
40	Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014. Otolaryngology - Head and Neck Surgery, 2017, 156, 285-288.	1.9	5
41	Educational utility of an online <scp>videoâ€based</scp> teaching tool for sinus and skull base surgery. Laryngoscope Investigative Otolaryngology, 2021, 6, 195-199.	1.5	4
42	Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020. JAMA Internal Medicine, 2021, 181, 1409.	5.1	4
43	Off-label Treatment in Otolaryngology—A Cautionary Tale. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 399.	2.2	3
44	CMS Adoption of Prior Authorization Requirements—Implications for Facial Plastic Surgery. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 397.	2.2	3
45	CARES Act Provider Relief Fund Aid to Otolaryngologists in Small Practices. Otolaryngology - Head and Neck Surgery, 2021, 164, 542-544.	1.9	3
46	Graduate Medical Education in Otolaryngology: Making Dollars and Sense of Reform. Otolaryngology - Head and Neck Surgery, 2021, 165, 762-764.	1.9	3
47	Contemporary Incremental Healthcare Costs for Allergic Rhinitis in the United States. Laryngoscope, 2022, 132, 1510-1514.	2.0	3
48	Compensation Rates for Otolaryngologic Procedures Under the Medicare Physician Fee Schedule in 2018. Laryngoscope, 2021, 131, E1785-E1791.	2.0	3
49	Variation in the Price of Head and Neck Surgical Oncology Procedures. Otolaryngology - Head and Neck Surgery, 2023, 168, 536-539.	1.9	3
50	Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005â€2014. Otolaryngology - Head and Neck Surgery, 2017, 156, 683-692.	1.9	2
51	Device Safety. Otolaryngologic Clinics of North America, 2019, 52, 103-114.	1.1	2
52	Price Transparency for COVID-19 Testing Among Top US Hospitals. Journal of General Internal Medicine, 2021, 36, 245-247.	2.6	2
53	Physician Performance in the Medicare Merit-based Incentive Payment System. JAMA - Journal of the American Medical Association, 2021, 325, 308.	7.4	2
54	Medicare Reform of Hospital Payment for Inpatient Facial Plastic Procedures. Facial Plastic Surgery and Aesthetic Medicine, 2021, 23, 2-4.	0.9	2

#	Article	IF	CITATIONS
55	Analyzing Charge Data Systematically Overestimates Health Care Costs. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 921.	2.2	2
56	Preserving and Promoting Competition in the Post–Coronavirus Disease 2019 Healthcare Delivery System. JAMA Health Forum, 2020, 1, e201191.	2.2	2
57	Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979–2015. Ophthalmology, 2017, 124, 1237-1246.	5.2	2
58	Medical Device User Fee Reauthorization — Back to Basics or Looking Ahead?. New England Journal of Medicine, 2022, 387, 196-199.	27.0	2
59	Commentary: Diagnostic devices in clinical trials have high stakes for patient care. BMJ, The, 2016, 354, i5197.	6.0	1
60	The Centers for Medicare & Medicaid Services' Overhaul of Office-Visit Payments—What's the Bottom Line for Otolaryngology?. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 303.	2.2	1
61	National Geographical Variation in Sinus Balloon Dilation. Otolaryngology - Head and Neck Surgery, 2020, 162, 761-766.	1.9	1
62	Moving Toward Equitable Telemedicine in Otolaryngology–Head and Neck Surgery—Reply. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 220.	2.2	1
63	Otolaryngologist Performance in the Merit-Based Incentive Payment System in 2018. Otolaryngology - Head and Neck Surgery, 2021, , 019459982110328.	1.9	1
64	Surprise Billing in Health Care. JAMA - Journal of the American Medical Association, 2021, 326, 569.	7.4	1
65	Defining the Health Utility Value of Medical Management of Chronic Rhinosinusitis: A Prospective Pilot Study. OTO Open, 2022, 6, .	1.4	1
66	Hospital Prices for Pediatric Tympanostomy Tube Placement and Adenotonsillectomy in 2021. Laryngoscope, 0, , .	2.0	1
67	Payer-negotiated pricing of the hypoglossal nerve stimulator. Journal of Clinical Sleep Medicine, 0, , .	2.6	1
68	The Case for Value-Based Pricing of Corticosteroid-Eluting Sinus Stents. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 221.	2.2	0
69	Otolaryngologists Trail Other Specialties in Industry Payments From Dermal Filler Companies. Laryngoscope, 2021, , .	2.0	0
70	Incomplete Picture of Otolaryngologist Performance in the Merit-Based Incentive Payment System—Reply. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 1087.	2.2	0
71	Refining Assumptions About Specialty Compensation Rates. JAMA Surgery, 2020, 155, 1085.	4.3	0